<- Go Home
Probiotec Limited
Probiotec Limited engages in the development, manufacture, packing, distribution, and sale of prescription and over the counter pharmaceuticals, complementary medicines and consumer health products, and fast-moving consumer products in Australia and internationally. The company provides contract manufacturing services for solid dose tablets, capsules, and caplets; tablets coatings; blister packs, bottles, sachets, tubs, and tubes; liquids, creams, gels, lotions, ointments, and powders and powder blends. It is also involved in analytical and stability testing services; new product formulation and production trials, and ongoing research and development services; and packaging options for human and animal nutrition products, as well as manufactures and exports a range of nutraceuticals and functional ingredient raw materials. The company was incorporated in 1996 and is headquartered in Laverton North, Australia. As of June 18, 2024, Probiotec Limited operates as a subsidiary of PYFA Australia Pty Ltd.
Market Cap
AUD 242.3M
Volume
56.2K
Cash and Equivalents
AUD 12.8M
EBITDA
AUD 27.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
AUD 66.3M
Profit Margin
29.95%
52 Week High
AUD 3.03
52 Week Low
AUD 2.13
Dividend
N/A
Price / Book Value
2.74
Price / Earnings
28.64
Price / Tangible Book Value
57.11
Enterprise Value
AUD 315.6M
Enterprise Value / EBITDA
9.38
Operating Income
AUD 19.0M
Return on Equity
10.18%
Return on Assets
5.09
Cash and Short Term Investments
AUD 12.8M
Debt
AUD 86.1M
Equity
AUD 88.3M
Revenue
AUD 221.2M
Unlevered FCF
AUD 5.4M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium